• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对在胆汁中循环的药物的非房室曲线下面积测定。

Noncompartmental area under the curve determinations for drugs that cycle in the bile.

作者信息

Colburn W A, Lucek R W

机构信息

Pharmacokinetics/Drug Metabolism, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105.

出版信息

Biopharm Drug Dispos. 1988 Sep-Oct;9(5):465-75. doi: 10.1002/bod.2510090505.

DOI:10.1002/bod.2510090505
PMID:3224163
Abstract

Drugs that are involved in the enterohepatic circulation (EHC) generally exhibit complex disposition profiles and are difficult to describe by classical methods. A noncompartmental method for calculating the area under the curve from time zero to time infinity (AUC) for substances that are involved the EHC is developed and tested. Previous methods have been based on specific compartmental models and/or have been limited to a single enterohepatic cycle. The current method uses the following equations: (formula; see text) for an IV dose or (formula; see text) for an oral dose where kaR is the apparent first-order absorption rate constant and beta R is the rate constant that describes the decline in blood concentrations of drug at 24-h intervals, i.e., 12, 36, and 60 or 24, 48, and 72 h, etc. AUC0-24 can be calculated by trapezoidal summation. The precision of this method is dependent on the number of observations during the 0-24 h sampling period as well as the accuracy of kaR and beta R. For drugs that are subject to a distinct distribution phase(s), error can be introduced into the AUC0-infinity value if pseudo-equilibrium has not been achieved during the first 24-hour interval. Although the method depends on a linearization process, it is truly concompartmental ('model-independent') in nature.

摘要

参与肠肝循环(EHC)的药物通常具有复杂的处置过程,难以用传统方法描述。本文开发并测试了一种用于计算参与EHC的物质从零时间到无穷时间曲线下面积(AUC)的非房室方法。以前的方法基于特定的房室模型和/或仅限于单个肠肝循环。当前方法使用以下公式:静脉注射剂量时为(公式;见原文),口服剂量时为(公式;见原文),其中kaR是表观一级吸收速率常数,βR是描述药物血药浓度在24小时间隔(即12、36和60小时或24、48和72小时等)下降的速率常数。AUC0-24可通过梯形求和计算。该方法的精度取决于0-24小时采样期内的观察次数以及kaR和βR的准确性。对于具有明显分布相的药物,如果在第一个24小时间隔内未达到伪平衡,则可能会将误差引入AUC0-无穷大值。尽管该方法依赖于线性化过程,但本质上它是真正的非房室(“与模型无关”)方法。

相似文献

1
Noncompartmental area under the curve determinations for drugs that cycle in the bile.针对在胆汁中循环的药物的非房室曲线下面积测定。
Biopharm Drug Dispos. 1988 Sep-Oct;9(5):465-75. doi: 10.1002/bod.2510090505.
2
Mean residence time for drugs subject to enterohepatic cycling.经历肠肝循环的药物的平均驻留时间。
J Pharmacokinet Biopharm. 1989 Jun;17(3):327-45. doi: 10.1007/BF01061900.
3
Pharmacokinetic Simulation and Area under the Curve Estimation of Drugs Subject to Enterohepatic Circulation.肠肝循环药物的药代动力学模拟及曲线下面积估计
Pharmaceutics. 2024 Aug 6;16(8):1044. doi: 10.3390/pharmaceutics16081044.
4
A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation.一种用于分析经历肠肝循环的药物处置曲线的药代动力学模型。
J Pharm Pharmacol. 2002 Jul;54(7):929-34. doi: 10.1211/002235702760089045.
5
Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey.恒河猴肠肝循环的群体药代动力学建模
Eur J Pharm Sci. 2005 Oct;26(2):151-61. doi: 10.1016/j.ejps.2005.05.010.
6
Absorption and enterohepatic circulation of baicalin in rats.大鼠体内黄芩苷的吸收及肠肝循环
Life Sci. 2005 Nov 26;78(2):140-6. doi: 10.1016/j.lfs.2005.04.072. Epub 2005 Aug 16.
7
General treatment of the enterohepatic recirculation of drugs and its influence on the area under the plasma level curves, bioavailability, and clearance.药物肝肠循环的一般处理及其对血浆浓度曲线下面积、生物利用度和清除率的影响。
Pharm Res. 1992 Oct;9(10):1306-13. doi: 10.1023/a:1015861502354.
8
The area function method for assessing the drug absorption rate in linear systems with zero-order input.用于评估具有零阶输入的线性系统中药物吸收速率的面积函数法。
Pharm Res. 1989 Feb;6(2):133-9. doi: 10.1023/a:1015928509101.
9
Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.在轻度和中度肝硬化患者中,阿芬太尼诱导的瞳孔缩小作为阿芬太尼药代动力学的替代指标。
Clin Pharmacokinet. 2007;46(3):261-70. doi: 10.2165/00003088-200746030-00006.
10
An equation for the systemic availability of drugs undergoing simultaneous enterohepatic cycling, first-pass metabolism, and intestinal elimination.一个用于描述同时经历肠肝循环、首过代谢和肠道消除的药物的全身可用性的方程。
Pharm Res. 1987 Jun;4(3):195-9. doi: 10.1023/a:1016447826075.

引用本文的文献

1
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.肠肝循环:生理、药代动力学及临床意义。
Clin Pharmacokinet. 2002;41(10):751-90. doi: 10.2165/00003088-200241100-00005.